Nyrada Inc. announced the publication of a peer-reviewed scientific paper in the preeminent Journal of Lipid Research, authored by Nyrada's Chief Scientific Officer, Dr. Benny Evison and Director of Preclinical Development, Dr. Alexandra Suchowerska. For many individuals at risk of cardiovascular disease, statin monotherapy is often insufficient to achieve their LDL-cholesterol targets. The study confirmed the suitability of NYX-PCSK9i as a potential oral treatment that could be combined with a statin in a single pill, for the large cohort of patients that cannot reach their targeted LDL-cholesterol levels taking a statin alone.

About the APOE*3-Leiden.CETP mouse model: Nyrada selected a specialised mouse model for the study called the APOE*3-Leiden.CETP mouse model, which has been specifically generated to possess human-like characteristics concerning cholesterol metabolism and cardiovascular health. The model expresses three human genes to specifically model the human hyperlipidaemia condition and is very well regarded in the cardiovascular field, having been used for over 170 drug intervention studies by the pharmaceutical industry over the last 15 years.